232 related articles for article (PubMed ID: 29848495)
21. Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study.
Shen JI; Saxena AB; Vangala S; Dhaliwal SK; Winkelmayer WC
BMC Nephrol; 2017 Jun; 18(1):196. PubMed ID: 28623899
[TBL] [Abstract][Full Text] [Related]
22. Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: Results from the Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker and Contrast Induced Nephropathy in Patients Receiving Cardiac Catheterization (CAPTAIN) trial.
Bainey KR; Rahim S; Etherington K; Rokoss ML; Natarajan MK; Velianou JL; Brons S; Mehta SR;
Am Heart J; 2015 Jul; 170(1):110-6. PubMed ID: 26093871
[TBL] [Abstract][Full Text] [Related]
23. Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use and cardiovascular outcomes in patients initiating peritoneal dialysis.
Shen JI; Saxena AB; Montez-Rath ME; Chang TI; Winkelmayer WC
Nephrol Dial Transplant; 2017 May; 32(5):862-869. PubMed ID: 27190342
[TBL] [Abstract][Full Text] [Related]
24. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592
[TBL] [Abstract][Full Text] [Related]
25. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
Zhang Y; He D; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Coronary Artery Disease without Heart Failure in the Modern Statin Era: a Meta-Analysis of Randomized-Controlled Trials.
Hoang V; Alam M; Addison D; Macedo F; Virani S; Birnbaum Y
Cardiovasc Drugs Ther; 2016 Apr; 30(2):189-98. PubMed ID: 26861251
[TBL] [Abstract][Full Text] [Related]
27. Evaluating prescription of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in patients with diabetes and albuminuria.
Chienwichai K; Chaloemwa P; Sangkaew S; Chang A
Clin Nephrol; 2024 Jun; 101(6):277-286. PubMed ID: 38606848
[TBL] [Abstract][Full Text] [Related]
28. Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease.
Fröhlich H; Nelges C; Täger T; Schwenger V; Cebola R; Schnorbach J; Goode KM; Kazmi S; Katus HA; Cleland JG; Clark AL; Frankenstein L
Am Heart J; 2016 Aug; 178():28-36. PubMed ID: 27502849
[TBL] [Abstract][Full Text] [Related]
29. Medical Therapy Utilization and Long-Term Outcomes Following Percutaneous Coronary Intervention: Five-Year Results From the Veterans Affairs Clinical Assessment, Reporting, and Tracking System Program.
Xie JX; Gunzburger EC; Kaun L; Plomondon ME; Barón AE; Waldo SW; Virani SS; Maddox TM; Mavromatis K
Circ Cardiovasc Qual Outcomes; 2019 Nov; 12(11):e005455. PubMed ID: 31665896
[TBL] [Abstract][Full Text] [Related]
30. Comparative Effectiveness of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in Individuals With Advanced CKD: A Nationwide Observational Cohort Study.
Fu EL; Clase CM; Evans M; Lindholm B; Rotmans JI; Dekker FW; van Diepen M; Carrero JJ
Am J Kidney Dis; 2021 May; 77(5):719-729.e1. PubMed ID: 33246024
[TBL] [Abstract][Full Text] [Related]
31. Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction.
Gilstrap LG; Fonarow GC; Desai AS; Liang L; Matsouaka R; DeVore AD; Smith EE; Heidenreich P; Hernandez AF; Yancy CW; Bhatt DL
J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28189999
[TBL] [Abstract][Full Text] [Related]
32. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials.
Xie X; Liu Y; Perkovic V; Li X; Ninomiya T; Hou W; Zhao N; Liu L; Lv J; Zhang H; Wang H
Am J Kidney Dis; 2016 May; 67(5):728-41. PubMed ID: 26597926
[TBL] [Abstract][Full Text] [Related]
33. Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes.
Vart P; Vaduganathan M; Jongs N; Remuzzi G; Wheeler DC; Hou FF; McCausland F; Chertow GM; Heerspink HJL
Clin J Am Soc Nephrol; 2022 Dec; 17(12):1754-1762. PubMed ID: 36414316
[TBL] [Abstract][Full Text] [Related]
34. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers have no effect on the outcomes of endovascular revascularization in tibial arterial occlusive disease.
Juneja A; Zia S; Abeysekara A; Shams S; Singh K; Schor J; Deitch J
Vascul Pharmacol; 2020 Aug; 131():106764. PubMed ID: 32629143
[TBL] [Abstract][Full Text] [Related]
35. Angiotensin I-converting enzyme inhibitors/angiotensin II receptor blockers may reduce tumor recurrence in left-sided and early colorectal cancers.
Ozawa T; Hashiguchi Y; Yagi T; Fukushima Y; Shimada R; Hayama T; Tsuchiya T; Nozawa K; Iinuma H; Ishihara S; Matsuda K
Int J Colorectal Dis; 2019 Oct; 34(10):1731-1739. PubMed ID: 31478086
[TBL] [Abstract][Full Text] [Related]
36. Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease.
Huang RS; Cheng YM; Zeng XX; Kim S; Fu P
Chin Med J (Engl); 2016 Mar; 129(5):562-9. PubMed ID: 26904991
[TBL] [Abstract][Full Text] [Related]
37. Angiotensin-converting enzyme inhibitors or angiotensin receptor blocker monotherapy retard deterioration of renal function in Taiwanese chronic kidney disease population.
Zheng CM; Wang JY; Chen TT; Wu YC; Wu YL; Lin HT; Chiu SP; Chang TJ; Zheng JQ; Chu NF; Lin YM; Su SL; Lu KC; Chen JS; Sung FC; Lee CT; Yang Y; Hwang SJ; Wang MC; Hsu YH; Chiou HY; Kao S; Wu MY; Lin YF
Sci Rep; 2019 Feb; 9(1):2694. PubMed ID: 30804406
[TBL] [Abstract][Full Text] [Related]
38. Proteinuria as a risk marker for the progression of chronic kidney disease in patients on predialysis care and the role of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment.
de Goeij MC; Liem M; de Jager DJ; Voormolen N; Sijpkens YW; Rotmans JI; Boeschoten EW; Dekker FW; Grootendorst DC; Halbesma N;
Nephron Clin Pract; 2012; 121(1-2):c73-82. PubMed ID: 23128440
[TBL] [Abstract][Full Text] [Related]
39. Renin-angiotensin system blocker discontinuation and adverse outcomes in chronic kidney disease.
Walther CP; Winkelmayer WC; Richardson PA; Virani SS; Navaneethan SD
Nephrol Dial Transplant; 2021 Sep; 36(10):1893-1899. PubMed ID: 33367872
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the stopping angiotensin converting enzyme inhibitor compared to angiotensin receptor blocker (STOP ACEi trial) in advanced and progressive chronic kidney disease.
Bhandari S; Mehta S; Khawaja A; Cleland JGF; Ives N; Cockwell P
Kidney Int; 2024 Jan; 105(1):200-208. PubMed ID: 37783444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
